Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

Purpose: The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathologic and molecular data. Experimental Design: Radiological, pathologic, and molecular data were correlated with trial clinical information to retrospectively re-evaluate event-free survival (EFS) and overall survival (OS). Results: One-hundred thirteen patients were randomized to the RT/TMZ arm (n = 54) or the RT/TMZ+BEV (BEV arm; n = 59). The tumor arose in the cerebral hemispheres in 68 patients (Cerebral group) and a midline location in 45 cases (Midline group). Pathologic diagnosis was available in all cases and molecular data in 86 of 113. H3 K27M histone mutations were present in 23 of 32 Midline cases and H3 G34R/V mutations in 7 of 54 Cerebral cases. Total/near-total resection occurred in 44 of 68 (65%) Cerebral cases but in only 5 of 45 (11%) Midline cases (P < 0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) at relapse were more frequent in Midline (17/45) than in Cerebral tumors (10/68, P < 0.05). Mean OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (P < 0.05). Pseudoprogression occurred in 8 of 111 (6.2%) cases. Conclusions: This study has shown that the poor outcome of midline tumors (compared with cerebral) may be related to (1) lesser surgical resection, (2) H3 K27M histone mutations, and (3) higher leptomeningeal dissemination.

[1]  P. Morgan,et al.  Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas , 2019, American Journal of Neuroradiology.

[2]  David T. W. Jones,et al.  Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial , 2018, Cancer cell.

[3]  Pieter Wesseling,et al.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.

[4]  P. Morgan,et al.  Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Aboian,et al.  Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis , 2017, American Journal of Neuroradiology.

[6]  C. Balañà,et al.  Pseudoprogression as an adverse event of glioblastoma therapy , 2017, Cancer medicine.

[7]  Satoshi O. Suzuki,et al.  A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.

[8]  P. V. van Laar,et al.  Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis , 2017, Clinical Neuroradiology.

[9]  M. Aboian,et al.  Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation , 2017, American Journal of Neuroradiology.

[10]  P. Morgan,et al.  Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas , 2016, American Journal of Neuroradiology.

[11]  Arie Perry,et al.  Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.

[12]  David T. W. Jones,et al.  Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.

[13]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[14]  A. Reiner,et al.  Sex, Age, Anatomic Location, and Extent of Resection Influence Outcomes in Children With High-grade Glioma. , 2015, Neurosurgery.

[15]  David T. W. Jones,et al.  Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers , 2015, Acta Neuropathologica.

[16]  Mark P. Richardson,et al.  A Critical Role for Network Structure in Seizure Onset: A Computational Modeling Approach , 2014, Front. Neurol..

[17]  C. Dardis,et al.  Leptomeningeal Metastases in High-Grade Adult Glioma: Development, Diagnosis, Management, and Outcomes in a Series of 34 Patients , 2014, Front. Neurol..

[18]  S. Baker,et al.  The genetic signatures of pediatric high-grade glioma: no longer a one-act play. , 2014, Seminars in radiation oncology.

[19]  C. Hawkins,et al.  Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications , 2014, Acta Neuropathologica.

[20]  David T. W. Jones,et al.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.

[21]  Theodoros N. Arvanitis,et al.  Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours , 2013, European journal of cancer.

[22]  Darren Hargrave,et al.  Paediatric and adult malignant glioma: close relatives or distant cousins? , 2012, Nature Reviews Clinical Oncology.

[23]  W. Vandertop,et al.  Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. , 2012, Cancer treatment reviews.

[24]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[25]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[26]  Seung Hong Choi,et al.  Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. , 2011, Radiology.

[27]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Sahgal,et al.  Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[29]  A. Panigrahy,et al.  Neuroimaging of Pediatric Brain Tumors: From Basic to Advanced Magnetic Resonance Imaging (MRI) , 2009, Journal of child neurology.

[30]  F. Berthold,et al.  Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas , 2006, British Journal of Cancer.

[31]  Stefan Rutkowski,et al.  Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. , 2006, Anticancer research.

[32]  Mitchel S Berger,et al.  Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. , 2005, Journal of neurosurgery.

[33]  N. Muthukumar.  Ossification of the Ligamentum Flavum as a Result of Fluorosis Causing Myelopathy: Report of Two Cases , 2005, Neurosurgery.

[34]  S. Heiland,et al.  Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. , 2015, Neuro-oncology.

[35]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[36]  F. Gilles,et al.  Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children’s Cancer Group high-grade glioma study CCG-945 , 2014, Journal of Neuro-Oncology.

[37]  Kuniaki Saito,et al.  H3F3A K27M mutations in thalamic gliomas from young adult patients. , 2014, Neuro-oncology.

[38]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[39]  M. Taneda,et al.  Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome , 2005, Acta Neurochirurgica.

[40]  S. Bertolone,et al.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.